gMSC 1

Drug Profile

gMSC 1

Alternative Names: gMSC®1

Latest Information Update: 18 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Two Cells
  • Class Stem cell therapies
  • Mechanism of Action Cartilage replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Cartilage disorders

Most Recent Events

  • 14 Jul 2017 Phase-III clinical trials in Cartilage disorders in Japan (Parenteral) (JapicCTI-173603)
  • 05 Jun 2017 Twocells company plans a phase III trial for Cartilage disorders in Japan (JapicCTI-173603)
  • 25 Apr 2016 Chugai Pharmaceutical in-licenses Synovium-derived mesenchymal stem cells from Two Cells for development in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top